Insulin lispro pens recalled for temperature exposure during distribution
Cardinal Health is recalling Humalog KwikPen insulin lispro pens distributed in New Mexico due to exposure to improper temperatures caused by inclement weather.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I recall. The severity rubric specifies that FDA Class I recalls receive a minimum score of 4, indicating a serious condition with potential for adverse health consequences.
Plain-English summary
Cardinal Health Inc. is recalling Humalog KwikPen insulin lispro injection, U-100, in prefilled pens with Box NDC 0002-8799-59. The recall affects pens distributed in New Mexico.
According to the recall notice, the products were exposed to temperatures outside their labeled storage conditions due to inclement weather during distribution.
Patients who have received affected pens should contact their healthcare provider to determine if the product should be used, and may contact Cardinal Health for further information regarding the recall.
The recalled product
- Product
- HUMALOG (INSULIN LISPRO)
- Brand
- HUMALOG
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug — Insulin / Injectable
- Hazard
- temperature-abuse
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Unknown
Distribution
Distributed in 1 state:
- NM
Related recalls
Same brand · HUMALOG
- HighEli Lilly Recalls Humalog Sterile Diluent Due to Manufacturing Deviations
FDA (Drugs) · 2024-04-24
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01